We therefore sought to establish and characterize murine models of accelerated-phase MPN with concomitant JAK/STAT activation and IDH mutations to identify the disease mechanism and test novel mechanism-based combination therapies. This evidence concerns the gene IDH2 and myeloproliferative neoplasm.